You know a dystopian show has gone off the rails when it introduces a baby character as a symbol of hope. Shame on you, Squid Game. The good news is that Ink Game has no ham-fisted morality lessons.

Biotechnology company Pandorum Technologies has raised $18 million in a Series B funding round to advance and market tissue regenerative therapies. Pandorum specialises in programmable regenerative ...

Pandorum Technologies has raised $18 million in a Series B funding round to advance clinical development and expand market access for its regenerative therapies. The India and US-based biotechnology ...

Biotechnology firm Pandorum Technologies has raised $18 million (Rs 163 crore) in a Series B round to advance the clinical development of its therapies that target diseases on the surface of the eye.

The funding round led by Protons Corporate, with participation from Galentic Pharma, Noblevast Advisory and Avinya Fund, Burman Family, among others The fresh capital will be deployed to advance the ...

Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global ...

For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...

BENGALURU, India & SAN CARLOS, Calif., February 09, 2026--(BUSINESS WIRE)--Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and ...

Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the closing of a US$ 18 million in Series B ...

March 6, 2026: We checked for new Warframe codes. What are the new Warframe codes? If you're on the hunt for free glyphs and cosmetics, you're in luck - we've got a complete list of available codes ...

QuantX will deploy Series B proceeds toward IND-enabling advancement of oral STAT6 and IL-17 inhibitors in immunology/inflammation and continued discovery expansion on its computational platform.